Roche Collaboration And Biologics Pipeline Will Expand Healthcare Reach

Shared on01 May 25
Fair value Decreased 2.24%

Shared on23 Apr 25
Fair value Increased 1.01%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on17 Apr 25
Fair value Increased 0.81%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on09 Apr 25
Fair value Increased 0.061%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on02 Apr 25
Fair value Increased 4.39%

AnalystConsensusTarget has increased shares outstanding growth rate from 0.0% to 0.0%.

Shared on26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on19 Mar 25
Fair value Decreased 6.33%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Shared on12 Mar 25
Fair value Increased 0.69%